Parker Waichman LLP Headlines by Topic
Gadolinium
Fewer Kidney Patients Received Gadolinium Agents Following 2006 NSF Alert
Nov 4, 2010
| Parker Waichman LLP
Fewer kidney patients have received gadolinium contrast dyes during MR studies since the US Food & Drug Administration (FDA) first issued...
FDA Stregnthens Warnings on Gadolinium MRI Dyes
Sep 9, 2010
| Parker Waichman LLP
Gadolinium-based contrast dyes will now bear new warnings on their labels regarding their association with nephrogenic systemic fibrosis (NSF),...
Omniscan, Magnevist and OptiMARK Associated with Most NSF Cases
Jun 24, 2010
| Parker Waichman LLP
Omniscan by GE Healthcare, Magnevist by Bayer Healthcare Pharmaceuticals and Covidien’s OptiMARK are linked to the highest number of...
Dutch Regulators Fault GE for Failing to Report Omniscan NSF Case
Jun 18, 2010
| Parker Waichman LLP
The Danish Medicines Agency has charged that GE Healthcare violated Dutch law when it failed to promptly and completely inform regulators about a...
Judge’s Omniscan Ruling Good News for Plaintiffs
May 6, 2010
Attorneys representing hundreds of plaintiffs in Omniscan lawsuits have been given a wide berth by a judge overseeing the litigation. In a 58-page...
GE Healthcare Advised to Restrict Omniscan in 2006
Apr 19, 2010
| Parker Waichman LLP
GE Healthcare’s own experts recommended in May 2006 that it proactively restrict the use of Omniscan, a gadolinium contrast dye, after it was...
Omniscan UK Libel Case Stifles Criticism, Doctor Claims
Dec 21, 2009
| Parker Waichman LLP
A Danish radiologist who was among the first to warn that gadolinium contrast dyes could be associated with nephrogenic systemic fibrosis (NSF) says...
First NSF Lawsuit to Go to Trial in California
Dec 10, 2009
| Parker Waichman LLP
One of the first trials involving a gadolinium contrast dye - Magnevist - and nephrogenic systemic fibrosis (NSF) is set to begin in...
OptiMark, Omniscan and Magnevist Carry Higher Risk, FDA Panel Says
Dec 9, 2009
| Parker Waichman LLP
OptiMark, Omniscan and Magnevist gadolinium contrast dyes appear to place people with severe kidney disease at a higher risk of nephrogenic systemic...
Restrict Some Gadolinium Contrast Dyes, FDA Panel Says
Dec 8, 2009
| Parker Waichman LLP
The use of some gadolinium contrast dyes should be restricted because of their association with nephrogenic systemic fibrosis (NSF), according to a...
